Reducing ICI dose frequency in cancer patients led to more deaths, prompting early trial termination and highlighting risks of less frequent dosing.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-low advanced breast cancer, regardless of ...

The combination of osimertinib and savolitinib improves survival in patients with EGFR-mutated NSCLC with MET alterations ...

The novel antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) continues to show significant survival benefits for patients with EGFR mutated nonsquamous non-small cell lung cancer (NSCLC) ...

Darolutamide plus ADT and radiotherapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone.

The combination of the individualized neoantigen therapy (INT) intismeran autogene plus pembrolizumab (Keytruda) significantly improved the recurrence-free survival (RFS) compared with placebo plus ...

The VOLGA trial showed that durvalumab plus EV improves EFS, OS, for patients with MIBC who don’t receive cisplatin-based ...

The early promise of therapeutic gold seen in clinical trials of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd; Enhertu) for HER2-low, hormone receptor (HR)-positive early-stage ...

The FDA granted traditional approval to pembrolizumab (Keytruda) or its subcutaneous formulation for patients with ...